{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:15:09Z","timestamp":1791040509870,"version":"4.1.0"},"reference-count":120,"publisher":"Informa UK Limited","issue":"26","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.2217\/fon-2022-0112","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T04:35:45Z","timestamp":1658291745000},"page":"2943-2966","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":41,"title":["Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review"],"prefix":"10.1080","volume":"18","author":[{"given":"Andrew","family":"Davies","sequence":"first","affiliation":[{"name":"Cancer Research UK Centre,University of Southampton,\rSouthampton,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon P","family":"Kater","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Centers,University of Amsterdam,\rAmsterdam,\rNetherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P","family":"Sharman","sequence":"additional","affiliation":[{"name":"Willamette Valley Cancer Institute & Research Center & US Oncology,\rEugene,\rOR 97401,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Ulm,Early Clinical Trials Unit (ECTU),Ulm,& Division of CLL,Department of Internal Medicine III,Ulm University,\rUlm,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"Medical Oncology,Candiolo Cancer Institute,FPO-IRCCS,\rCandiolo,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-7280","authenticated-orcid":false,"given":"Christian","family":"Klein","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Zurich,\rSchlieren,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Parreira","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd,\rBasel,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center,Department of Medicine,\rNY 10021,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.142.7.2560"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M800784200"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243543"},{"issue":"3","key":"e_1_3_2_6_1","first-page":"611","article-title":"Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression","volume":"5","author":"Davis TA","year":"1999","unstructured":"Davis TA , CzerwinskiDK, LevyR. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin. Cancer Res.5(3), 611\u2013615 (1999).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv303"},{"key":"e_1_3_2_8_1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues.","author":"Swerdlow SH","year":"2017","unstructured":"Swerdlow SH , CampoE, HarrisNLet al. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, France (2017)."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00448"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"issue":"6","key":"e_1_3_2_12_1","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross P","year":"2012","unstructured":"Boross P , LeusenJH. Mechanisms of action of CD20 antibodies. Am. J. Cancer Res.2(6), 676\u2013690 (2012).","journal-title":"Am. J. Cancer Res."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz9356"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S34273"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.09.008"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2184"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.4.2600"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-263533"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/11539590-000000000-00000"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1182"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000381524"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-305847"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8008"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2031"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08428.x"},{"key":"e_1_3_2_32_1","unstructured":"Rituximab Highlights of Prescribing Information. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103705s5311lbl.pdf (Accessed September 2021) (2021)."},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15232"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04125.x"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009337512"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30078-9"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9585"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-404368"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408773"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2139"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00163"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15710"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7504"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2165"},{"issue":"1","key":"e_1_3_2_45_1","first-page":"1267","article-title":"Greater efficacy and potency of obinutuzumab compared with rituximab in chronic lymphocytic leukemia patients confirmed by a semi-mechanistic pharmacokinetic\/pharmacodynamic model","volume":"130","author":"Kamisoglu K","year":"2017","unstructured":"Kamisoglu K , PhippsA, JamoisCet al. Greater efficacy and potency of obinutuzumab compared with rituximab in chronic lymphocytic leukemia patients confirmed by a semi-mechanistic pharmacokinetic\/pharmacodynamic model. Blood130(Suppl. 1), 1267 (2017).","journal-title":"Blood"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-586610"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-481341"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1515940"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-613570"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_3_2_52_1","first-page":"abstract S151","article-title":"Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study","volume":"215923","author":"Goede V","year":"2018","unstructured":"Goede V , FischerK, DyerMJet al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. EHA Library215923, abstract S151 (2018).","journal-title":"EHA Library"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186387"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17326"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30443-5"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7509"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01485-x"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122482"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1011641"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01580"},{"key":"e_1_3_2_65_1","article-title":"A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR\/BR) in frontline Chronic Lymphocytic Leukemia (CLL) of fit patients: first co-primary endpoint analysis of the international intergroup GAIA (CLL13) trial","author":"Eichhorst B","year":"2021","unstructured":"Eichhorst B , NiemannC, KaterAPet al. A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR\/BR) in frontline Chronic Lymphocytic Leukemia (CLL) of fit patients: first co-primary endpoint analysis of the international intergroup GAIA (CLL13) trial. AsH Online Program. Available at: https:\/\/ash.confex.com\/ash\/2021\/webprogram\/Paper146161.html (Accessed January 2022) (2021).","journal-title":"AsH Online Program"},{"key":"e_1_3_2_66_1","article-title":"High resolution assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and high-sensitivity Flow Cytometry (hsFCM) in the phase III GAIA (CLL13) trial","author":"F\u00fcrstenau M","year":"2021","unstructured":"F\u00fcrstenau M , SchilhabelA, RobrechtSet al. High resolution assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and high-sensitivity Flow Cytometry (hsFCM) in the phase III GAIA (CLL13) trial. AsH Online Program., Available at: https:\/\/ash.confex.com\/ash\/2021\/webprogram\/Paper147729.html (Accessed January 2022) (2021).","journal-title":"AsH Online Program."},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547869"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879429"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00491"},{"key":"e_1_3_2_71_1","article-title":"Phase II study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia","author":"Huber H","year":"2021","unstructured":"Huber H , EdenhoferS, von TresckowJet al. Phase II study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia. Blood, (2021).","journal-title":"Blood"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0313-8"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30414-5"},{"key":"e_1_3_2_74_1","first-page":"1316","article-title":"Bendamustine followed by obinutuzumab and idelalisib in patients with chronic lymphocytic leukemia (CLL): CLL2-BCG trial of the German CLL Study Group (GCLLSG)","author":"Cramer P","year":"2020","unstructured":"Cramer P , Von TresckowJ, FinkAMet al. Bendamustine followed by obinutuzumab and idelalisib in patients with chronic lymphocytic leukemia (CLL): CLL2-BCG trial of the German CLL Study Group (GCLLSG). AsH Online Program, 1316 (2020).","journal-title":"AsH Online Program"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00455-1"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00307-0"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9348"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714162"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-839688"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01738-2"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8023"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.613.613"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209015"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30097-3"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123422"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30089-4"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131045"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.3656"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0559-9"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-670802"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8960"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-059469"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01215.x"},{"issue":"2","key":"e_1_3_2_94_1","article-title":"Obinutuzumab can be administered as a 90-minute short-duration infusion (SDI) in patients with previously untreated follicular lymphoma: GAZELLE end of induction analysis","volume":"39","author":"H\u00fcbel K","year":"2021","unstructured":"H\u00fcbel K , BuchholzTA, IzutsuKet al. Obinutuzumab can be administered as a 90-minute short-duration infusion (SDI) in patients with previously untreated follicular lymphoma: GAZELLE end of induction analysis. Hematological Oncol.39(S2), (2021).","journal-title":"Hematological Oncol."},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01578"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13495"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011568"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01418-8"},{"key":"e_1_3_2_99_1","unstructured":"Hernandez J NielsenT KleinC WengerM. Obinutuzumab for the treatment of non-Hodgkin lymphomas. Available at: www.nature.com\/articles\/d42473-018-00278-8 (Accessed September 2021) (2021)."},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013526"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129422"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7505"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115930"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00900-7"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0282-y"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008750"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0455"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123949"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-658401"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.227892"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3270"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123633"},{"key":"e_1_3_2_115_1","unstructured":"Tabari E LovejoyAF LinHet al. Genetically defined subtypes of DLBCL from targeted panel on plasma match previously described tumor tissue subtypes. EHA25. Available at: https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/293781\/ehsan.tabari.genetically.defined.subtypes.of.dlbcl.from.targeted.panel.on.html (Accessed October 2021) (2020)."},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124687"},{"key":"e_1_3_2_117_1","unstructured":"Raval A TracyS RayJet al. Risk profiling of first-line DLBCL patients by measuring circulating tumor DNA. EHA25. Available at: https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/293704\/aparna.raval.risk.profiling.of.first-line.dlbcl.patients.by.measuring.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1 (Accessed October 2021) (2020)."},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_136"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.14_2629"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30291-X"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008727"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3651"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:46:18Z","timestamp":1719110778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":120,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.2217\/fon-2022-0112"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0112","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}